REGENXBIO Inc. announced positive data from the Phase II fellow eye sub-study evaluating subretinal delivery of ABBV-RGX-314 in patients with bilateral wet age-related macular degeneration (wet AMD) on October 21, 2024.
The data, presented at the American Academy of Ophthalmology meeting, showed a 97% reduction in annualized anti-VEGF treatment burden at nine months. Furthermore, 100% of patients required either zero or one supplemental injection, and 78% were completely injection-free.
ABBV-RGX-314 was well tolerated in the treated fellow eye with no drug-related serious adverse events as of September 11, 2024. Patients also demonstrated sustained best-corrected visual acuity and central retinal thickness at nine months.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.